These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24460671)

  • 1. Lead optimization on conventional non-steroidal anti-inflammatory drugs: an approach to reduce gastrointestinal toxicity.
    Narsinghani T; Sharma R
    Chem Biol Drug Des; 2014 Jul; 84(1):1-23. PubMed ID: 24460671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
    Hippisley-Cox J; Coupland C; Logan R
    BMJ; 2005 Dec; 331(7528):1310-6. PubMed ID: 16322018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cyclooxygenase inhibition on the gastrointestinal tract.
    Radi ZA; Khan NK
    Exp Toxicol Pathol; 2006 Nov; 58(2-3):163-73. PubMed ID: 16859903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forthcoming non-steroidal anti-inflammatory drugs: are they really devoid of side effects?
    Bjarnason I
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S27-36. PubMed ID: 10379467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacological profile of 2-(8-methyl-10,11-dihydro-11-oxodibenz[b,f]oxepin-2-yl)propionic acid (AD-1590), a new non-steroidal anti-inflammatory agent with potent antipyretic activity.
    Nakamura H; Yokoyama Y; Motoyoshi S; Ishii K; Imazu C; Seto Y; Kadokawa T; Shimizu M
    Arzneimittelforschung; 1983; 33(11):1555-69. PubMed ID: 6607053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The safety of COX-2 inhibitors].
    Lakatos G; Herszényi L; Tulassay Z
    Orv Hetil; 2008 Aug; 149(33):1539-47. PubMed ID: 18687572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats].
    Laudanno OM; Cesolari JA; Esnarriaga J; Flaherty P; Vada J; Guastalli G; San Miguel P; Bedini OA
    Acta Gastroenterol Latinoam; 1998; 28(3):249-55. PubMed ID: 9773153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
    Fiorucci S; Santucci L; Distrutti E
    Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2].
    Tada Y; Nagasawa K
    Nihon Rinsho; 1999 Feb; 57(2):419-24. PubMed ID: 10078017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New NSAIDs and gastroduodenal damage.
    Folco GC
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
    Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide release is not required to decrease the ulcerogenic profile of nonsteroidal anti-inflammatory drugs.
    Jain S; Tran S; El Gendy MA; Kashfi K; Jurasz P; Velázquez-Martínez CA
    J Med Chem; 2012 Jan; 55(2):688-96. PubMed ID: 22148253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-steroidal anti-inflammatory drugs and intestinal side effects].
    Stadnicki A; Frysz-Naglak D
    Wiad Lek; 2007; 60(5-6):286-90. PubMed ID: 17966896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathogenesis of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs].
    Lamarque D
    Gastroenterol Clin Biol; 2004 Apr; 28 Spec No 3():C18-26. PubMed ID: 15366671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upper gastrointestinal complications related to non-steroidal anti-inflammatory drugs--what have we achieved so far?
    Wong VW; Leong RW; Chan FK
    Dig Liver Dis; 2004 Jan; 36(1):1-3. PubMed ID: 14971808
    [No Abstract]   [Full Text] [Related]  

  • 19. Combining anticholinergic and anti-inflammatory activities into a single moiety: a novel approach to reduce gastrointestinal toxicity of ibuprofen and ketoprofen.
    Halen PK; Chagti KK; Giridhar R; Yadav MR
    Chem Biol Drug Des; 2007 Nov; 70(5):450-5. PubMed ID: 17927723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [NSAIDs and its gastrointestinal side effects: relation of NSAIDs variety and influence of concomitant medicine].
    Iwakiri R
    Nihon Rinsho; 2007 Oct; 65(10):1776-80. PubMed ID: 17926523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.